JAN 09, 2015 12:00 AM PST

Vaxil Vaccine Immunotherapy Helps Immune System to Repel

WRITTEN BY: Ilene Schneider
Cancer kills 8 million people worldwide every year, 14 million new cancer cases are diagnosed annually and finding a cure for various types of it has proven elusive.

Research into using cancer vaccines to activate of the immune system to treat cancer has increased significantly in recent years. The first therapeutic cancer vaccine for prostate cancer was approved by the FDA in 2010. Now there are several other therapeutic cancer vaccines in development.

Cancer vaccines are said to be highly specific with limited side effects. The market for cancer vaccines is poised to dramatically increase to over $7 billion by 2015, as therapeutic vaccines become used both as a stand-alone front-line treatment and as a combination treatment with other existing therapies.

Vaxil Biotheraputics, an Israeli biotechnology company is developing a vaccine that is designed to prevent cancer from returning. The company, based in Nes Ziona, Israel, has developed ImMucin, a prophylactic cancer vaccine that can trigger a response in about 90 percent of all types of cancer. According to Julian Levy, Vaxil's CFO, the company is "trying to harness the natural power of the immune system to fight against cancer by seeking out cancer cells and destroying them."

ImMucin is a 21-mer synthetic vaccine composed of the entire signal peptide domain of the MUC1 protein. ImMucin is intended to stimulate the patient's own immune system to control cancer by reacting to the natural corresponding MUC1 antigen as expressed on the surface of cancer cells.

The vaccine is not a replacement for traditional cancer treatments such as chemotherapy or radiation. Instead, Vaxil is targeting a different stage in the patient's battle against cancer, specifically the early stages of the detection, as well as during remission. Because the drug requires a relatively healthy body in order to be fully effective, it will not be helpful to cancer patients in advanced stages of the disease. Unlike traditional vaccines, ImMucin is given to people who are already sick, and it acts like a drug that has physiological effects when introduced to the body.

ImMucin stimulates a part of the immune system and guides it to attack cells with markers that indicate the presence of cancer. According to the company, by introducing the drug during an early stage of cancer, it trains the patient's immune system to destroy cancer cells if the disease recurs.

ImMucin is a small and defined domain expressed only on tumor cells and not in the blood stream. It does not contain any non-specific epitopes that could reduce specific anti-cancer immunity. ImMucin was shown to selectively be expressed on tumor cells in association with MHC molecules to ensure specific anti-cancer activity. ImMucin can bind multiple MHC Class I and Class II alleles for broader immunity by multiple T cell clones, and it is applicable to the entire population. It has internal antigen-specific "adjuvant-like" properties that can reduce the need for additional external adjutants. It can efficiently deal with immune escape mechanism mediated by cancer cells.

Extensive preclinical studies have demonstrated that mMucin is highly effective in inducing a robust and broad T cell immunity against MUC1 expressing tumors in various in-vitro assays. In in vivo studies, the anti-MUC1 immunity induced by ImMucin performed better than other MUC1-dervied peptide epitopes including the antigen sequence in the BLP-25 vaccine (Merck AG) currently in Phase III studies. This immune response has been consistent throughout Vaxil's clinical trials on the vaccine during the past few years. Vaxil ran trials exclusively on multiple myeloma patients until January 2014, when it began trials on breast cancer patients.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 22, 2019
Cancer
NOV 22, 2019
The cancerous fear of circular extrachromosomal DNA
New research published in Nature suggests that ring-shaped extrachromosomal DNA (ecDNA) is particularly abundant in tumor cells and plays a malicious role ...
NOV 25, 2019
Cell & Molecular Biology
NOV 25, 2019
Linking Intestinal Stem Cells with Increased Cancer Risk From a High-Fat Diet
The work, which used a mouse model, links stem cell activity with cellular fat consumption in a new way....
JAN 11, 2020
Cancer
JAN 11, 2020
Should we be concerned about talc powder and ovarian cancer?
After the outcry against baby powder and concerns regarding its link to ovarian cancer, still, no investigations have clearly linked the product to the dis...
JAN 21, 2020
Cancer
JAN 21, 2020
A gene for leukemia triggers the growth of stem blood cells
New research from the University of Colorado Cancer Center has identified a way to make hematopoietic stem cells from a gene that causes a type of leukemia...
FEB 07, 2020
Genetics & Genomics
FEB 07, 2020
Mutations That Lead to Cancer May Occur Decades Before Diagnosis
As our cells age or divide, errors can accumulate in the genome they carry, which can lead to cancer, and a variety of environmental and genetic factors ca...
FEB 18, 2020
Cancer
FEB 18, 2020
Are you at risk of endometrial cancer?
Are you concerned about endometrial cancer? New research published recently in the Journal of Medical Genetics has identified 24 genetic variants that...
Loading Comments...